Targanta’s Oritavancin Study Design Could Be Regulatory Hurdle
Executive Summary
Targanta may need to conduct additional clinical trials of its intravenous antibiotic oritavancin if FDA does not accept the company's use of a 15 percent noninferiority delta in its Phase III trial, according to the firm's initial public offering prospectus filed May 11 with the Securities & Exchange Commission
You may also be interested in...
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 1 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.